Drugs / Maraviroc
Maraviroc
also known as
MVC · UK-427,857 · Selzentry · Celsentri · Maraviroc(Selzentry) · Maraviroc = Celsentri · Rel-maraviroc
Other / unclassified targets CCR5 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 7 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (5) | US (FDA) | SELZENTRY | — | 2008-11-25 – 2020-10-30 | fda.gov ↗ |
| Approved | EU (EMA) | Celsentri | — | 2007-09-18 | europa.eu ↗ |
| Approved | US (FDA) | SELZENTRY | — | 2007-08-06 | fda.gov ↗ |
Trials 117 · started per year
today
US approved 2007
EU approved 2007
1
1
3
7
9
14
11
15
8
6
6
9
3
7
2
1
3
2
1
1
2
2
20032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT02431273 | Jun 2015 → Dec 2016 | — | Auritec Pharmaceuticals | Completed | No outcome recorded |
| Phase 0 | NCT02486510 | Jul 2012 → Dec 2015 | HIV infectious disease | Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal | Terminated | No outcome recorded |
| Phase 125 trials | ||||||
| Phase 1 | NCT04435522 | Oct → Dec 2020 | COVID-19 | Rhode Island Hospital | Completed | No outcome recorded |
| Phase 1 | NCT03274804 | Apr 2018 → Mar 2020 | colorectal cancer | University Hospital Heidelberg | Completed | No outcome recorded |
| Phase 1 | NCT02778204 | Jun 2017 → Sep 2019 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT04721301 | Jan 2017 → Mar 2023 | malignant pancreatic neoplasm, metastatic malignant neoplasm in the colon | University Hospital Heidelberg | Completed | No outcome recorded |
| Phase 1 | NCT02625207 | Nov 2015 → Mar 2016 | — | ViiV Healthcare | Completed | No outcome recorded |
| Phase 1 | NCT02480894 | Jul → Sep 2015 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
| Phase 1 | NCT02346084 | Jan → Dec 2015 | HIV infectious disease | International Partnership for Microbicides, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02039323 | Feb → Apr 2014 | — | University of North Carolina, Chapel Hill | Completed | No outcome recorded |
| Phase 1 | NCT01894776 | Jun → Dec 2013 | HIV infectious disease, Mycobacterium avium complex disease | Ottawa Hospital Research Institute | Completed | No outcome recorded |
| Phase 1 | NCT01980329 | Jan 2013 → Mar 2014 | Taqi polymorphism | Johns Hopkins University | Completed | No outcome recorded |
| Phase 1 | NCT01719627 | Oct 2012 → May 2014 | HIV infectious disease | Fight AIDS and Infectious Diseases Foundation | Completed | No outcome recorded |
| Phase 1 | NCT01627717 | Jun 2012 → Apr 2013 | — | University of Montreal Hospital Centre (CHUM) | Completed | No outcome recorded |
| Phase 1 | NCT01363037 | Nov 2011 → Aug 2012 | HIV infectious disease | International Partnership for Microbicides, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01348763 | Oct 2011 → Feb 2012 | HIV infectious disease | Imperial College London | Completed | No outcome recorded |
| Phase 1 | NCT01290211 | Apr → Jun 2011 | — | ViiV Healthcare | Completed | No outcome recorded |
| Phase 1 | NCT01133210 | Jan 2011 → Aug 2012 | hypertriglyceridemia | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 1 | NCT01242579 | Jan → Jul 2011 | HIV infectious disease | International Partnership for Microbicides, Inc. | Withdrawn | No outcome recorded |
| Phase 1 | NCT01140412 | Jul → Oct 2010 | — | ViiV Healthcare | Terminated | No outcome recorded |
| Phase 1 | NCT01056874 | Mar → Apr 2010 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
| Phase 1 | NCT00982878 | Sep 2009 → Jul 2010 | HIV infectious disease | Imperial College London | Completed | No outcome recorded |
| Phase 1 | NCT00821535 | Feb → May 2009 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
| Phase 1 | NCT00783484 | Oct 2008 → May 2009 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00775294 | May 2008 → May 2009 | HIV infectious disease | University of North Carolina, Chapel Hill | Completed | No outcome recorded |
| Phase 1 | NCT00703586 | Sep 2007 → May 2011 | HIV infectious disease | Rockefeller University | Completed | No outcome recorded |
| Phase 1 | NCT00496782 | Jul 2007 → Oct 2008 | HIV infectious disease | ViiV Healthcare | Terminated | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT02475915 | Jan → Nov 2015 | — | SEARCH Research Foundation | Completed | No outcome recorded |
| Phase 1/2 | NCT02167451 | Jul 2014 → Sep 2018 | graft versus host disease | Children's Hospital Medical Center, Cincinnati | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT00948753 | Jun 2009 → Apr 2011 | graft versus host disease | Abramson Cancer Center at Penn Medicine | Completed | No outcome recorded |
| Phase 229 trials · 1 met primary · 5 missed | ||||||
| Phase 2 | NCT06805656 | Jul 2026 → Jan 2027 expected | HIV infectious disease | Federal University of São Paulo | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06853223 | Dec 2025 → Apr 2028 expected | acute lung injury, disease related to transplantation | University of California, San Francisco | Recruiting | No outcome recorded |
| Phase 2 | NCT06640192 | May 2025 → Dec 2026 expected | HIV infectious disease | Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal | Recruiting | No outcome recorded |
| Phase 2 | NCT06511063 | Oct 2024 → Nov 2026 expected | long COVID-19 | Icahn School of Medicine at Mount Sinai | Recruiting | No outcome recorded |
| Phase 2 | NCT04789616 | Sep 2022 → Dec 2025 overdue | stroke disorder | University of Calgary | Recruiting | No outcome recorded |
| Phase 2 | NCT04475991 | Jul 2021 → Mar 2022 | COVID-19 | Hospital General de México Dr. Eduardo Liceaga | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT04710199 | Feb → Jul 2021 | viral infectious disease | Andalusian Public Foundation for Health Research in Seville | Completed | No outcome recorded |
| Phase 2 | NCT05932550 | Aug 2020 → Aug 2022 | — | Tel-Aviv Sourasky Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT04441385 | Jun 2020 → Feb 2021 | COVID-19 | Hospital Universitario Infanta Leonor | Terminated | No outcome recorded |
| Phase 2 | NCT02741323 | Jan 2017 → May 2022 | HIV infectious disease, kidney disorder | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT02208037 | Aug 2014 → Oct 2017 | Hodgkins lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, chronic myeloid leukemia, diffuse large B-cell lymphoma +2 | National Heart, Lung, and Blood Institute (NHLBI) | Completed | Mixed |
| Phase 2 | NCT02799888 | Apr 2014 → Dec 2016 | graft versus host disease | Affiliated Hospital to Academy of Military Medical Sciences | Unknown | No outcome recorded |
| Phase 2 | NCT01785810 | Feb 2013 → Nov 2016 | hematopoietic and lymphoid cell neoplasm | Abramson Cancer Center at Penn Medicine | Completed | No outcome recorded |
| Phase 2 | NCT01505114 | Jun 2012 → Nov 2015 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT01400412 | Jan 2012 → Jun 2014 | HIV infectious disease | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | Completed | Met primary |
| Phase 2 | NCT01420523 | Dec 2011 → Apr 2013 | HIV infectious disease, localized lipodystrophy | ANRS, Emerging Infectious Diseases | Terminated | Missed primary |
| Phase 2 | NCT01291459 | Sep 2011 → Dec 2015 | HIV infectious disease | Association Pour la Recherche en Infectiologie | Unknown | No outcome recorded |
| Phase 2 | NCT01276236 | Mar 2011 → Jan 2015 | Kaposi's sarcoma | University of California, San Francisco | Completed | No outcome recorded |
| Phase 2 | NCT01019551 | Sep 2010 → Jul 2012 | HIV infectious disease | Objectif Recherche Vaccins SIDA | Completed | Missed primary |
| Phase 2 | NCT00993148 | May 2010 → Apr 2013 | HIV infectious disease | Northwestern University | Completed | No outcome recorded |
| Phase 2 | NCT00987948 | Jan 2010 → Nov 2012 | HIV infectious disease | University of Hawaii | Completed | No outcome recorded |
| Phase 2 | NCT00976404 | Nov 2009 → Jul 2013 | HIV infectious disease | Robert L. Murphy | Completed | Missed primary |
| Phase 2 | NCT00944541 | Sep 2009 → Aug 2010 | HIV infectious disease | French National Agency for Research on AIDS and Viral Hepatitis | Completed | No outcome recorded |
| Phase 2 | NCT00791700 | Apr 2009 → Apr 2015 | HIV infectious disease | ViiV Healthcare | Unknown | No outcome recorded |
| Phase 2 | NCT00827112 | Mar 2009 → Jul 2010 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
| Phase 2 | NCT00795444 | Mar 2008 → Jan 2015 | — | Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal | Completed | Missed primary |
| Phase 2 | NCT00427934 | Feb 2007 → Oct 2008 | rheumatoid arthritis | Pfizer | Terminated | Missed primary |
| Phase 2 | NCT00634959 | Jul → Dec 2003 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
| Phase 2 | NCT00643643 | Oct 2002 → Jun 2003 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
| Phase 2/37 trials · 1 met primary · 3 missed | ||||||
| Phase 2/3 | NCT03172026 | Aug 2019 → Oct 2020 | stroke disorder | University of California, Los Angeles | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2/3 | NCT03129113 | Mar 2017 → Nov 2020 | HIV infectious disease, fatty liver disease | University College, London | Completed | No outcome recorded |
| Phase 2/3 | NCT02159027 | Jun 2015 → Feb 2019 | AIDS dementia complex | University of Hawaii | Completed | No outcome recorded |
| Phase 2/3 | NCT01154673 | Nov 2011 → Sep 2014 | — | University of Toronto | Completed | Missed primary |
| Phase 2/3 | NCT00624195 | Mar 2007 → Feb 2012 | HIV infectious disease | University of California, San Diego | Completed | Missed primary |
| Phase 2/3 | NCT00098748 | Nov 2004 → Dec 2005 | HIV infectious disease | ViiV Healthcare | Completed | Missed primary |
| Phase 2/3 | NCT00098306 | Nov 2004 → Apr 2007 | HIV infectious disease | ViiV Healthcare | Completed | Met primary |
| Phase 313 trials · 1 met primary · 3 missed | ||||||
| Phase 3 | NCT02588820 | Apr 2016 → Nov 2018 | HIV infectious disease | David Garcia Cinca | Unknown | No outcome recorded |
| Phase 3 | NCT03708861 | Jan 2016 → Dec 2017 | HIV infectious disease | University of Turin, Italy | Withdrawn | No outcome recorded |
| Phase 3 | NCT03178084 | Oct 2014 → Nov 2016 | HIV infectious disease | Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal | Completed | No outcome recorded |
| Phase 3 | NCT01896921 | Sep 2013 → Dec 2018 | HIV infectious disease | University of Maryland, Baltimore | Completed | No outcome recorded |
| Phase 3 | NCT01345630 | Sep 2011 → Aug 2013 | — | ViiV Healthcare | Terminated | Missed primary |
| Phase 3 | NCT00935480 | Oct → Nov 2010 | HIV infectious disease | Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer | Completed | Missed primary |
| Phase 3 | NCT01033760 | Apr 2010 → Jul 2013 | HIV infectious disease | ANRS, Emerging Infectious Diseases | Completed | Missed primary |
| Phase 3 | NCT00808002 | Feb 2009 → Nov 2011 | HIV infectious disease | Germans Trias i Pujol Hospital | Completed | No outcome recorded |
| Phase 3 | NCT00719823 | Aug 2008 → May 2010 | HIV infectious disease | ViiV Healthcare | Withdrawn | No outcome recorded |
| Phase 3 | NCT00537394 | Jan 2008 → May 2012 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | Met primary |
| Phase 3 | NCT00478231 | Jul 2007 → Aug 2010 | AIDS | ViiV Healthcare | Completed | No outcome recorded |
| Phase 3 | NCT00426660 | Feb 2007 → Jun 2010 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
| Phase 3 | NCT00098293 | Nov 2004 → Apr 2007 | — | ViiV Healthcare | Completed | Mixed |
| Phase 427 trials · 5 missed | ||||||
| Phase 4 | NCT07668505 | Sep 2026 → Aug 2029 expected | myositis disease | Chinese University of Hong Kong | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT04965662 | Jan 2018 → Mar 2021 | HIV infectious disease | Guy's and St Thomas' NHS Foundation Trust | Completed | No outcome recorded |
| Phase 4 | NCT03218592 | Jun 2017 → Dec 2018 | AIDS | University of North Carolina, Chapel Hill | Completed | No outcome recorded |
| Phase 4 | NCT03163277 | May 2017 → Jun 2020 | HIV infectious disease, cognitive disorder | Giovanni Di Perri | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT02990312 | May 2017 → Jul 2019 | HIV infectious disease | University of Maryland, Baltimore | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT02519777 | Apr 2016 → Dec 2019 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | Missed primary |
| Phase 4 | NCT03402815 | Jan 2015 → Apr 2017 | HIV infectious disease, atherosclerosis | University Of Perugia | Completed | No outcome recorded |
| Phase 4 | NCT01866267 | Jan → Dec 2013 | AIDS | St. Hope Foundation | Completed | No outcome recorded |
| Phase 4 | NCT01367236 | Jan 2013 → Oct 2015 | HIV infectious disease, cognitive disorder | Imperial College London | Completed | Missed primary |
| Phase 4 | NCT01680536 | Nov 2012 → Nov 2015 | HIV infectious disease | St Stephens Aids Trust | Completed | No outcome recorded |
| Phase 4 | NCT01533272 | Feb 2012 → Jun 2014 | HIV infectious disease | Hospital Clinic of Barcelona | Completed | Missed primary |
| Phase 4 | NCT01449006 | Oct 2011 → Sep 2014 | HIV infectious disease, post-viral disorder | Bruce Brew | Completed | No outcome recorded |
| Phase 4 | NCT01367210 | Jun 2011 → Jun 2015 | HIV infectious disease | Catholic University of the Sacred Heart | Terminated | No outcome recorded |
| Phase 4 | NCT01378910 | Jun 2011 → Apr 2014 | HIV infectious disease | Fight AIDS and Infectious Diseases Foundation | Completed | No outcome recorded |
| Phase 4 | NCT01275625 | Jun 2011 → Oct 2012 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
| Phase 4 | NCT01327547 | May 2011 → Apr 2013 | coinfection | ViiV Healthcare | Completed | Missed primary |
| Phase 4 | NCT01068873 | Apr → Dec 2010 | HIV infectious disease | Temple University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT01013987 | Feb 2010 → ? | AIDS | Fundación Huésped | Unknown | No outcome recorded |
| Phase 4 | NCT01190293 | Jan 2010 → Mar 2012 | HIV infectious disease | St Stephens Aids Trust | Completed | No outcome recorded |
| Phase 4 | NCT00981318 | Dec 2009 → May 2015 | AIDS | Rodwick, Barry M., M.D. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT00966329 | Oct 2009 → May 2012 | HIV infectious disease | Germans Trias i Pujol Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00884858 | Apr 2009 → Apr 2011 | HIV infectious disease | ASST Fatebenefratelli Sacco | Completed | Missed primary |
| Phase 4 | NCT00925756 | Oct 2008 → May 2012 | HIV infectious disease | University of California, San Diego | Completed | No outcome recorded |
| Phase 4 | NCT00735072 | Sep 2008 → Apr 2010 | HIV infectious disease | University of California, San Francisco | Completed | No outcome recorded |
| Phase 4 | NCT00717067 | Jul → Nov 2008 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
| Phase 4 | NCT00666705 | Feb → Mar 2008 | — | ViiV Healthcare | Completed | No outcome recorded |
| Phase 4 | NCT01235013 | — | HIV infectious disease | Hospital Clinic of Barcelona | Unknown | No outcome recorded |
| Phase not applicable8 trials · 2 missed | ||||||
| — | NCT02961829 | Jul 2015 → Mar 2019 | HIV infectious disease | Federal University of São Paulo | Completed | No outcome recorded |
| — | NCT02333045 | Jan 2015 → Oct 2016 | HIV infectious disease | Emory University | Terminated | No outcome recorded |
| — | NCT02134717 | Jan 2014 → May 2015 | pulmonary sarcoidosis | University of Pittsburgh | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT02934022 | Jun 2012 → Dec 2014 | HIV infectious disease | Southern California Institute for Research and Education | Completed | No outcome recorded |
| — | NCT01204905 | Sep 2010 → May 2014 | HIV infectious disease | University of Maryland, Baltimore | Completed | No outcome recorded |
| — | NCT00988780 | Dec 2009 → Mar 2013 | HIV infectious disease, immune reconstitution inflammatory syndrome | National Institute of Medical Sciences and Nutrition Salvador Zubiran | Unknown | Missed primary |
| — | NCT00709111 | Jan → Oct 2009 | HIV infectious disease | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | Completed | Missed primary |
| — | NCT00525733 | Oct 2007 → Dec 2013 | HIV infectious disease | Rockefeller University | Completed | No outcome recorded |
| Phase not stated3 trials | ||||||
| — | NCT00801515 | Aug 2009 → Jul 2011 | HIV infectious disease | ViiV Healthcare | No longer available | No outcome recorded |
| — | NCT01776996 | — | HIV infectious disease | ViiV Healthcare | No longer available | No outcome recorded |
| — | NCT00992654 | — | HIV infectious disease | ViiV Healthcare | No longer available | No outcome recorded |
| Comparator or background therapy27 trials | ||||||
| Phase 1 | NCT03060447 Background | May 2017 → Feb 2020 | HIV infectious disease | Gilead Sciences | Completed | No outcome recorded |
| Phase 1 | NCT01749566 Comparator | Dec 2012 → May 2015 | HIV infectious disease | Emory University | Completed | No outcome recorded |
| Phase 1 | NCT01597895 Comparator | Jul → Aug 2012 | — | ViiV Healthcare | Completed | No outcome recorded |
| Phase 1 | NCT00771823 Comparator | May → Nov 2008 | HIV infectious disease | St Stephens Aids Trust | Completed | No outcome recorded |
| Phase 2 | NCT07080567 Comparator | Jul 2025 → Dec 2027 expected | ischemic stroke | Emmanuel Carrera | Recruiting | No outcome recorded |
| Phase 2 | NCT04966429 Comparator | May 2021 → Apr 2024 | cognitive disorder | Tel-Aviv Sourasky Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT00764465 Comparator | Oct → Dec 2008 | — | Garden State Infectious Disease Associates, PA | Completed | No outcome recorded |
| Phase 2/3 | NCT06974084 Comparator | Jul → Dec 2026 expected | long COVID-19 | HealthBio, Inc. | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT00098722 Comparator | Dec 2004 → Apr 2007 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
| Phase 3 | NCT03631732 Comparator | Aug 2018 → Aug 2019 | HIV infectious disease | Gilead Sciences | Completed | Met primary |
| Phase 3 | NCT02469246 Background | Jun 2015 → Dec 2017 | HIV infectious disease | Gilead Sciences | Completed | Met primary |
| Phase 3 | NCT02302547 Comparator | Dec 2014 → Aug 2017 | HIV infectious disease | University Hospital, Tours | Completed | No outcome recorded |
| Phase 3 | NCT02121795 Background | May 2014 → Aug 2015 | HIV infectious disease | Gilead Sciences | Completed | Met primary |
| Phase 3 | NCT01348308 Comparator | Sep 2011 → Mar 2016 | AIDS | ANRS, Emerging Infectious Diseases | Completed | No outcome recorded |
| Phase 3 | NCT00844519 Comparator | Jan 2010 → Dec 2012 | HIV infectious disease, cardiovascular disorder | University of California, San Francisco | Completed | No outcome recorded |
| Phase 3 | NCT00708162 Background | Jul 2008 → Dec 2010 | HIV infectious disease | Gilead Sciences | Completed | Met primary |
| Phase 3 | NCT00440271 Background | Feb 2007 → Oct 2008 | HIV infectious disease | Boehringer Ingelheim | Terminated | No outcome recorded |
| Phase 4 | NCT02881762 Comparator | Jun 2017 → Mar 2019 | HIV infectious disease, hepatitis C virus infection | University of Maryland, Baltimore | Completed | No outcome recorded |
| Phase 4 | NCT01637259 Comparator | Jun 2012 → Dec 2015 | HIV infectious disease, proteinuria | Kirby Institute | Completed | No outcome recorded |
| Phase 4 | NCT01389063 Comparator | Jan 2012 → Sep 2014 | — | S.F.L. van Lelyveld | Unknown | No outcome recorded |
| Phase 4 | NCT01384682 Comparator | Aug 2011 → Dec 2015 | HIV infectious disease | Kirby Institute | Completed | No outcome recorded |
| Phase 4 | NCT00981773 Comparator | Sep 2009 → Mar 2013 | HIV infectious disease | Imperial College London | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT01049204 Comparator | Jul 2009 → Jun 2011 | HIV infectious disease | St Stephens Aids Trust | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT00870363 Comparator | Apr 2009 → Apr 2013 | HIV infectious disease | University of California, Davis | Completed | No outcome recorded |
| Phase 4 | NCT00782301 Comparator | Mar 2009 → Feb 2010 | HIV infectious disease, chronic hepatitis C virus infection, hepatitis B virus infection | ViiV Healthcare | Withdrawn | No outcome recorded |
| Phase 4 | NCT00875368 Comparator | Feb 2009 → Dec 2011 | HIV infectious disease | S.F.L. van Lelyveld | Completed | No outcome recorded |
| Phase 4 | NCT00853840 Comparator | Apr → May 2008 | AIDS | ViiV Healthcare | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2014-07-22 | Pfizer | Results ViiV Healthcare presents phase III data comparing once-daily maraviroc in combination with darunavir/ritonavir with emtricitabine/tenofovir plus darunavir/ritonavir in treatment-naïve adults with HIV-1 pfizer.com ↗
The proportion of study participants who were virologically suppressed (HIV-1 RNA <50 copies/mL) at week 48 was 77.3% for MVC+DRV/r compared to 86.8% for FTC /TDF +DRV/r (95% confidence interval -15.0% to -4.4%). |
| 2014-07-22 | GlaxoSmithKline | Results ViiV Healthcare presents phase III data gsk.com ↗
The proportion of study participants who were virologically suppressed (HIV-1 RNA <50 copies/mL) at week 48 was 77.3% for MVC+DRV/r compared to 86.8% for FTC /TDF +DRV/r (95% confidence interval -15.0% to -4.4%). |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2014-07-22 | Pfizer | ViiV Healthcare presents phase III data comparing once-daily maraviroc in combination with darunavir/ritonavir with emtricitabine/tenofovir plus darunavir/ritonavir in treatment-naïve adults with HIV-1 pfizer.com ↗ |
| 2014-07-22 | GlaxoSmithKline | ViiV Healthcare presents phase III data gsk.com ↗ |
Evidence & citations 12 cited values
Every value below carries the sentence it was read from. 148 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Maraviroc | “Generic names: Efavirenz/Emtricitabine/Tenofovir, Lamivudine/Zidovudine, Emtricitabine, Lamivudine, Abacavir/Lamivudine, Zidovudine, Abacavir/Lamivudine/Zidovudine,...” NCT00624195 ↗142“The three antiretroviral drugs have been chosen because they are the only ones that allow administration at higher doses without causing increased toxicity: dolutegravir 50...” NCT06640192 ↗ “This is an open-label protocol designed to provide continued access to maraviroc to only those subjects who have completed previous studies of maraviroc and continue to receive...” NCT01776996 ↗ “Current ART regimen plus raltegravir and maraviroc Raltegravir : 400 mg PO BID for 56 weeks Maraviroc : 150, 300 or 600 mg PO BID depending on concomitant ART treatment, for 56 weeks” NCT01019551 ↗ “The following agents are allowed as part of the ART regimen: nucleoside reverse transcriptase inhibitors, raltegravir, dolutegravir (DTG), rilpivirine, and maraviroc.” NCT03060447 ↗ “We randomly assigned for 48 weeks 22 patients to continue their current first line regimen of Truvada® plus Kaletra® or intensify it with Maraviroc and Raltegravir.” PMID 25320633 ↗ Oct 2014 “A triple combination IVR building on this platform and delivering TDF-FTC along with the antiretroviral (ARV) agent maraviroc (MVC) also is under development.” PMID 30265679 ↗ Sep 2018 “Maraviroc inhibits CCR5-tropic HIV-1 across different subtypes in vitro and has demonstrated efficacy in clinical trials.” PMID 34160290 ↗ Jan 2021 “efavirenz (EFV), rilpivirine (RPV), raltegravir (RAL), dolutegravir (DTG), maraviroc (MVC), or nevirapine (NVP)” NCT02469246 ↗ “Tenofovir+Emtricitabine+Third agent (Including a fusion inhibitor: enfuvirtide or a CCR5 antagonist :maraviroc” NCT02302547 ↗ “As of today, maraviroc is the only CCR5-antagonist approved for HIV treatment.” NCT01378910 ↗ |
| Known as | Celsentri | “Maraviroc brand name in the EC is Celsentri.” NCT00884858 ↗3“maraviroc (Celsentri®): 150 mg bid.” NCT01033760 ↗ “maraviroc (Selzentry, Celsentri)” NCT07668505 ↗ “Maraviroc (Celsentri)” NCT01348308 ↗ |
| Known as | Maraviroc = Celsentri | “Maraviroc = Celsentri” NCT01190293 ↗ |
| Known as | Maraviroc(Selzentry) | “Maraviroc (Selzentry)” NCT01068873 ↗1“Maraviroc(Selzentry)” NCT01204905 ↗ |
| Known as | MVC | “The primary objective was to assess the effect of MVC intensification on latently infected CD4(+) T cells in chronically HIV-1-infected patients receiving antiretroviral...” PMID 22174752 ↗ Dec 201116“A strategy to modulate activation and trafficking of leukocytes to the lungs is by blocking CCR5 by using maraviroc (MVC), which has shown capable of modulating conditions of...” NCT04475991 ↗ “A single arm, open-labeled trial was conducted to examine the effect of maraviroc (MVC) intensification on monocyte inflammation and neuropsychological (NP) performance in 15...” PMID 25227930 ↗ Sep 2014 “Maraviroc (MVC) is a member of a new class of antiretroviral compounds known as small molecule CCR5 antagonists that block R5 HIV entry into cluster of differentiation 4 (CD4) cells.” NCT01276236 ↗ “A triple combination IVR building on this platform and delivering TDF-FTC along with the antiretroviral (ARV) agent maraviroc (MVC) also is under development.” PMID 30265679 ↗ Sep 2018 “Maraviroc (MVC) is a CCR5 antagonist that prevents virus entry blocking the binding of R5-tropic HIV to the cell surface CCR5 co-receptor.” NCT01190293 ↗ “Maraviroc (MVC), a chemokine receptor 5 antagonist, is a potential alternative component of therapy in those with R5-tropic virus.” PMID 27048747 ↗ Apr 2016 “efavirenz (EFV), rilpivirine (RPV), raltegravir (RAL), dolutegravir (DTG), maraviroc (MVC), or nevirapine (NVP)” NCT02469246 ↗ “Use of Maraviroc (MVC) in Immunological Non-responder HIV-1-infected Patients.” NCT00884858 ↗ “Tablets: daily 300 mg oral maraviroc, Selzentry®,(MVC) for 8 consecutive days” NCT02346084 ↗ “Chemokine Receptor 5 (CCR5) Entry Inhibitor Maraviroc (MVC)” NCT00764465 ↗ |
| Known as | Rel-maraviroc | ChEMBL registry synonym — accepted as the source's own label CHEMBL256907 ↗ |
| Known as | Selzentry | “Maraviroc (Selzentry) is a HIV medication that works by blocking the entry of HIV in cells including monocytes/macrophages that use a receptor called CCR5.” NCT00987948 ↗4“by the CCR5 antagonist drug maraviroc (Selzentry) administered to healthy volunteers” NCT01719627 ↗ “Tablets: daily 300 mg oral maraviroc, Selzentry®,(MVC) for 8 consecutive days” NCT02346084 ↗ “maraviroc (Selzentry, Celsentri)” NCT07668505 ↗ |
| Known as | UK-427,857 | “Maraviroc (UK-427,857) 300 mg once daily added to Zidovudine/Lamivudine (300 mg/150 mg twice daily).” NCT03178084 ↗6“Maraviroc (UK-427,857), a selective and reversible CCR5 co-receptor antagonist” NCT00098748 ↗ “Maraviroc (UK-427,857), a selective and reversible CCR5 coreceptor antagonist” NCT00098306 ↗ “Maraviroc (UK-427,857), a selective and reversible CCR5 coreceptor antagonist” NCT00098293 ↗ “Maraviroc (UK-427,857), a selective and reversible CCR5 coreceptor antagonist” NCT00098722 ↗ “Maraviroc (UK-427,857)” NCT00634959 ↗ “Maraviroc (UK-427,857)” NCT00643643 ↗ |
| Action | Inhibit | “a selective and reversible CCR5 coreceptor antagonist” NCT00098293 ↗ |
| Modality | Other / unclassified | “Maraviroc is a new ART agent from a novel class of HIV inhibitors, entry inhibitors” NCT00870363 ↗ |
| Route | Oral | “300 mg (2- 150 mg tablets) are administered by mouth twice a day (BID) for 12 weeks.” NCT00427934 ↗ |
| Target | CCR5 | “a selective and reversible CCR5 coreceptor antagonist” NCT00098306 ↗ |